Mastocytosis Clinical Trials

41 clinical trials for Mastocytosis across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of Factors Regulating Mast Cell Proliferation — RECRUITING
• Assessment of somatosensory profiles using quantitative sensory testing (QST) in patients with mast cell activation disease (MCAD) — RECRUITING
• Institutional Registry of Rare Diseases — RECRUITING
• Analysis of the Role of IgE Proteoforms in Health and Disease — RECRUITING
• AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY IN PATIENTS WHO PARTICIPATED IN AN AVAPRITINIB CLINICAL STUDY — RECRUITING
• Myeloproliferative Neoplasms (MPNs) Patient Registry — RECRUITING
• Mastocytosis Registry (of Zurich) — RECRUITING
• Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis — RECRUITING
• (SUMMIT) A MULTI-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL STUDY OF THE SAFETY AND EFFICACY OF CGT9486 IN SUBJECTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS — RECRUITING · PHASE2
• A PHASE 2 OPEN-LABEL, MULTICENTER CLINICAL STUDY OF THE SAFETY, EFFICACY, PHARMACOKINETIC, AND PHARMACODYNAMIC PROFILES OF CGT9486 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS — RECRUITING · PHASE2
• (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis — ACTIVE_NOT_RECRUITING · PHASE2
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies — COMPLETED · PHASE2
• Pregnancy and Medically Assisted Conception in Rare Diseases — WITHDRAWN
• Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) — COMPLETED · PHASE2
• A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with Smouldering or Indolent Severe Systemic mastocytosis with handicap, unresponsive to optimal symptomatic treatment — OTHER · PHASE3
• Hydroxychloroquine in isolated cutaneous mastocytosis patients or indolent systemic mastocytosis with associated skin involvement patients: proof of concept study (HCQMa) — TERMINATED · PHASE3
• Cromoglicate in Mastocytosis — TERMINATED · PHASE2
• Physical well-being and movement behaviour of patients with myeloproliferative neoplasia (MPN) or mastocytosis — OTHER
• Study of Cellular Heterogeneity in Patients With Mastocytosis — OTHER · NA
• Angioedema Biomarker Research Study — OTHER
• Study of Mast Cell Precursors — COMPLETED
• Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate — COMPLETED · NA
• Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients — OTHER · PHASE2
• Mast Cell Connect: A Registry for Patients With Mastocytosis — COMPLETED
• Assessment of Burden Disease in Patients With Mast Cell Disorders — OTHER
• Mast Cell Activation Test in Allergic Disease — COMPLETED
• Cause and Natural Course of Pediatric-Onset Mastocytosis — COMPLETED
• Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders — TERMINATED
• The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy — COMPLETED
• Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis — COMPLETED · PHASE2
• Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation — COMPLETED · PHASE2
• AN OPEN-LABEL, SINGLE ARM, PHASE 2 STUDY TO EVALUATE EFFICACY AND SAFETY OF AVAPRITINIB (BLU-285), A SELECTIVE KIT MUTATION-TARGETED TYROSINE KINASE INHIBITOR, IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS — COMPLETED · PHASE2
• Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases — OTHER · NA
• Stem Cell Transplantation to Treat Systemic Mastocytosis — COMPLETED · PHASE2
• Molecular Mechanisms and Diagnosis of Mastocytosis — COMPLETED
• Study on Mastocytosis for Rupatadine Treatment — COMPLETED · PHASE2
• Treatment of Indolent Systemic Mastocytosis With PA101 — COMPLETED · PHASE2
• The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients — COMPLETED · PHASE2
• Characteristics of Mast Cells in Mastocytosis — COMPLETED
• Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing — COMPLETED
• Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals — COMPLETED

Refine this search